This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Spronk, P. E Articles by Kallenberg, C. G. Search for Related Content PubMed Articles by Spronk, P. E Articles by Kallenberg, C. G. Social Bookmarking                   What's this?

Review : Serological markers of disease activity in systemic lupus erythematosus

Department of Clinical Immunology, University Hospital Groningen

Pieter C Limburg

Department of Rheumatology, University Hospital Groningen, PO Box 30.001, 9700 RB, Groningen, The Netherlands

Cees GM Kallenberg

Department of Clinical Immunology, University Hospital Groningen

When measured serially by Farr assay at a frequency of approximately once a month, changes in levels of anti-dsDNA appear to be a good predictor of clinical disease activity. Although the role of antibodies to the RNA component of snRNP awaits further studies, measurement of anti-UsnRNP antibody levels seems to be of limited value in monitoring lupus patients in clinical practice. The same holds for antibodies to SSA (Ro) and anti-histone antibodies. More recently described antibodies to C1q are probably useful in the follow-up of SLE patients suspected of proliferative renal involvement. The best alternative to measuring levels of the antibodies mentioned before is probably serial analysis of activation of the complement cascade. Levels of complement factors like C3, C4 and, functionally, CH50 remain a useful parameter for monitoring disease activity in SLE, although fluctuations in anti-dsDNA as measured by Farr assay seem superior with respect to sensitivity and specificity for an ensuing relapse. Despite the problems in sampling, measuring levels of activated split products of complement factors like C3a, C3d or C5a may prove to be a valuable tool in the follow-up of lupus patients. The involvement of the endothelial surface is illustrated by rising sVCAM-1 levels prior to relapses in SLE. Although one could expect that subsequent inflammation should be reflected by increased levels of inflammatory molecules like CRP and IL-6, the use of these molecules as predictors of lupus activity seems limited. Interferon- as a direct reflector of the effector phase seems, however, rather promising in this respect and awaits longitudinal studies to analyse the possible relation with clinical disease activity and other serological parameters.

Key Words: review • serology • auto-antibodies • anti-DNA • SLE

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M Lidar, G Zandman-Goddard, Y Shinar, N Zaks, A Livneh, and P Langevitz Systemic lupus erythematosus and familial Mediterranean fever: a possible negative association between the two disease entities - report of four cases and review of the literature Lupus, July 1, 2008; 17(7): 663 - 669. [Abstract] [PDF]

				J. D. McBride, F. G. Gabriel, J. Fordham, T. Kolind, G. Barcenas-Morales, D. A. Isenberg, M. Swana, P. J. Delves, T. Lund, I. A. Cree, et al. Screening Autoantibody Profiles in Systemic Rheumatic Disease with a Diagnostic Protein Microarray That Uses a Filtration-Assisted Nanodot Array Luminometric Immunoassay (NALIA) Clin. Chem., May 1, 2008; 54(5): 883 - 890. [Abstract] [Full Text] [PDF]

				L De Rycke, D Baeten, E Kruithof, F Van den Bosch, E M Veys, and F De Keyser The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications Lupus, December 1, 2005; 14(12): 931 - 937. [Abstract] [PDF]

				M. A. Seelen, E. A. van der Bijl, L. A. Trouw, T. C. M. Zuiverloon, J. R. Munoz, F. C. Fallaux-van den Houten, N. Schlagwein, M. R. Daha, T. W. J. Huizinga, and A. Roos A role for mannose-binding lectin dysfunction in generation of autoantibodies in systemic lupus erythematosus Rheumatology, January 1, 2005; 44(1): 111 - 119. [Abstract] [Full Text] [PDF]

				J D Reveille Predictive value of autoantibodies for activity of systemic lupus erythematosus Lupus, May 1, 2004; 13(5): 290 - 297. [Abstract] [PDF]

				P. Bossu, D. Neumann, E. Del Giudice, A. Ciaramella, I. Gloaguen, G. Fantuzzi, C. A. Dinarello, E. Di Carlo, P. Musiani, P. L. Meroni, et al. IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease PNAS, November 25, 2003; 100(24): 14181 - 14186. [Abstract] [Full Text] [PDF]

				M. R. Arbuckle, M. T. McClain, M. V. Rubertone, R. H. Scofield, G. J. Dennis, J. A. James, and J. B. Harley Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus N. Engl. J. Med., October 16, 2003; 349(16): 1526 - 1533. [Abstract] [Full Text] [PDF]

				H. Sumichika, K. Sakata, N. Sato, S. Takeshita, S. Ishibuchi, M. Nakamura, T. Kamahori, S. Ehara, K. Itoh, T. Ohtsuka, et al. Identification of a Potent and Orally Active Non-peptide C5a Receptor Antagonist J. Biol. Chem., December 13, 2002; 277(51): 49403 - 49407. [Abstract] [Full Text] [PDF]

				N. Bizzaro and D. Villalta The predictive value of ANA and anti-dsDNA antibodies for flares in SLE Rheumatology, December 1, 2001; 40(12): 1422 - 1423. [Full Text] [PDF]

				E. Esfandiari, I. B. McInnes, G. Lindop, F.-P. Huang, M. Field, M. Komai-Koma, X.-q. Wei, and F. Y. Liew A Proinflammatory Role of IL-18 in the Development of Spontaneous Autoimmune Disease J. Immunol., November 1, 2001; 167(9): 5338 - 5347. [Abstract] [Full Text] [PDF]

				W. Egner The use of laboratory tests in the diagnosis of SLE J. Clin. Pathol., June 1, 2000; 53(6): 424 - 432. [Full Text] [PDF]

				S K Mak, E K. Lam, and A K. Wong Clinical profile of patients with late-onset SLE: not a benign subgroup Lupus, January 1, 1998; 7(1): 23 - 28. [Abstract] [PDF]

				P. Eggleton, K. Reid, U. Kishore, and R. Sontheimer Review : Clinical relevance of calreticulin in systemic lupus erythematosus Lupus, January 1, 1997; 6(7): 564 - 571. [Abstract] [PDF]